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trial. Country-speciﬁc unit costs data were obtained from national
sources. Costs are reported in 2007 euro. RESULTS: Iodixanol is
cost-effective compared to iohexol with both lower costs and
better effects related to fewer ADRs. For Germany, Italy, Spain,
Sweden, and UK, respectively, the mean per patient cost differ-
ences due to the reduction in ADRs were €444, €431, €574, €859,
and €753.CONCLUSIONS: Iodixanol results in fewer ADRs and
resulted in lower ADR costs per patient for this high risk patient
population across the ﬁve European countries.
PCV55
PHARMACOECONOMIC EVALUATION OFTREATMENT
WITH PROCORALAN® PREPARATION COMPAREDTO
INVASIVETREATMENT
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OBJECTIVES: To determine economic impact of Procoralan®
therapy in stable angina patients as compared to invasive PCI/
CABG therapy. METHODS: A cost-minimisation, probabilistic
model performed from a third party payer perspective in Poland.
Costs calculations were based on the National Health Fund rates.
Invasive therapy cost was assumed to be a weighted average of
PCI/CABG, according to Poland-speciﬁc proportions. Clinical
assumptions and risk proﬁles were derived from the Euro Heart
Survey. The economic impact was calculated for the patients not
qualiﬁed for invasive therapy or maintenance therapy with beta-
blocker due to contraindications or intolerance. Both one-way
(drug cost) and multi-way (revascularisation risk, reimbursement
level) sensitivity analyses were performed. RESULTS: The incre-
mental costs per patient per year were as follows: €747.82–743.34
for Procoralan® 5 mg/7.5 mg therapy respectively; € 3879.88 for
CABG, €2265.88 for PCI. The reduction in payer’s expenditure in
the range of €1918.32–1922.81 per patient per year was demon-
strated as a result of the application of Procoralan® 5 mg/7.5 mg
therapy instead of the invasive therapy. The obtained result applies
to the case of the whole Procoralan® price borne by the payer
(100% reimbursement). In the case of 70% and 50% reimburse-
ment rates savings amounted to €2112.09–2115.23 and
€2248.05–2250.20 depending on dose of the drug. The sensitivity
analyses results showed that change of the Procoralan® treatment
cost (+/-50%), wide range of changes in the risk of a secondary
revascularisation and the reimbursement level did not inﬂuence
the ultimate interpretation of the results. CONCLUSIONS: Third
party payer’s beneﬁts related to Procoralan® may apply to all
patients suffering from angina symptoms having contraindica-
tions or intolerance to beta-blocker. The greatest savings concern
patients not qualiﬁed for invasive therapy as no alternative treat-
ment is effective in this group, but in all scenarios the Procoralan®
therapy was proven to be cost-saving for public payer.
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OBJECTIVES: To compare the costs of induction of labor with
the costs of an expectant management strategy in women with
pregnancy-induced hypertension (PIH) or preeclampsia (PE) at
term. METHODS: The Hypertension and Preeclampsia Interven-
tion Trial At Term (HYPITAT) was a multicentre randomized
controlled clinical trial conducted in The Netherlands between
October 2005 and April 2008. Women diagnosed with PIH or PE
at 36 weeks of gestation were randomly allocated to either
induction of labor or expectant management. The study showed
that induction of labor reduced both maternal complications as
well as the caesarean section rate as compared to expectant
management. The economic analysis was performed from a soci-
etal perspective. Resource utilization was documented by speciﬁc
items in the Case Report Forms (CRF) and additional question-
naires. For most medical unit costs, we used estimates provided
by the ﬁnancial and economic departments of two participating
hospitals (one academic and one general hospital). For non-
medical costs and primary care costs Dutch standardized prices
were used. Sensitivity analyses were performed to explore the
impact of different assumptions and cost estimates on the results
of the costs analysis. RESULTS: Data of 756 women were ana-
lyzed. Mean costs per patient were €5400 for induction and
€6025 for expectant management (difference €625). This 10%
difference predominantly originated in the ante partum period:
per patient €977 for induction versus €1929 for expectant man-
agement. Comparable costs were found for delivery (€761 versus
€790 per patient). No substantial differences were found in the
post partum period. CONCLUSIONS: In women with PIH or PE
at term, costs associated with induction of labor are considerably
lower as compared to expectant management. This cost reduc-
tion is mainly due to differences in resource utilization in the ante
partum period.
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OBJECTIVES: To estimate the number and cost of cardiovascu-
lar (CV) events avoided over ﬁve years by treating with statins to
alternative low-density lipoprotein cholesterol (LDL-C) targets
of <3.0 mmol/L and <2.0 mmol/L, based on 1000 patients with
established cardiovascular disease (CVD) or diabetes from an
NHS perspective. METHODS: Proportional effects per mmol/L
LDL-C reduction for non-fatal myocardial infarction (MI), coro-
nary revascularisation and stroke were taken from a meta-
analysis of 14 randomised controlled trials of statin therapy.
Absolute risk reductions (ARR) between control and treatment
arms were calculated. Baseline LDL-C value of 3.6 mmol/L (SD
1.27) was taken from the Health Survey for England 2003 and
5000 LDL-C values 3.0 mmol/L and 2.0 mmol/L were ran-
domly generated from this distribution giving mean baseline
LDL-C values of 4.24 mmol/L and 3.86 mmol/L respectively.
Absolute LDL-C reductions needed to meet the alternative
targets were calculated and ARR in CV event incidence applied.
The % reduction in CV events for 1000 patients was used to
estimate number of CV events avoided; costs of events avoided
were calculated using the National Tariff 2007–08. RESULTS:
ARR between control and treatment arms was 1.8%, 1.8% and
0.6% for MI, coronary revascularisation and stroke respectively.
Absolute reduction required to meet the LDL-C target of
<3.0 mmol/L was 1.24 mmol/L resulting in 51 CV events
avoided (22 MIs; 22 CABG/PTCAs; 7 strokes), with a total cost
saving of £220,714 (MI = £70,158; CABG/PTCA = £130,368;
stroke = £20,188). The 1.86 mmol/L required to meet the LDL-C
target <2.0 mmol/L resulted in the 77 CV events avoided
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(33 MIs; 33 CABG/PTCAs; 11 strokes) with a total cost saving of
£332,512 (MI = £105,237; CABG/PTCA = £195,551; stroke =
£31,724). CONCLUSIONS: The estimated beneﬁt of treating to
an LDL-C target of <2.0 mmol/L rather than <3.0 mmol/L was
an additional 26 CV events avoided per 1000 patients with an
associated cost saving of £111,799.
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OBJECTIVES: A representative evaluation of CAD costs in
Poland including General Practitioners (GPs) and Specialists’ (S)
settings. METHODS: A representative sample of 2593 Polish
patients with conﬁrmed CAD (1977 patients under GP’s care,
616 patients under S care). A time horizon of the analysis was
12 month and a retrospective approach was applied. The study
estimated both direct medical and indirect costs resulted from
sick leaves, pensions and sickness beneﬁts. Unit costs were
obtained from available published data derived from the
National Health Fund and the Polish Social Insurance Institu-
tion. A prevalence based method using National Statistical
Ofﬁce data was used to estimate economic burden of CAD.
RESULTS: The distribution of total costs was similar in the
GPs’ and specialists’ settings. Hospitalisation and invasive treat-
ment constituted main direct medical costs’ drivers in both
conditions. The average direct medical cost per CAD patient
reached annually €1079.09. The average societal cost €1437.19
when the merely indirect costs related to the absence from
work (€358.10) was included. Average cost covering also indi-
rect cost related to the patients’ disability increased to the
€2254.17. The total average costs were signiﬁcantly (14.4%)
higher in Ss’ than in GPs’ settings. In accordance with the
lowest boundary estimate of CAD prevalence rate (2.9%), the
total, societal burden of CAD in Poland in 2005 amounted to
€2056.7 million. More than half of this cost (52.1%) was due
to the indirect cost, 69.5% of which resulted from patients’
disability. CONCLUSIONS: CAD imposes a high economic
burden for the third party payer as well as for Polish society.
Clearly, there is a need to develop and apply innovative, cost-
effective treatment strategies that will reduce the need for
hospitalisation and invasive treatment and may successfully be
implemented in the GPs’ practice.
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OBJECTIVES: We estimated incremental inpatient costs and
length of stay (LOS) attributable to secondary atrial ﬁbrillation
(AF) in patients with and without cardiac predisposing factors to
document the economic burden of this disease. METHODS: We
extracted 2004–2005 discharges from Premier Perspective(tm),
the largest hospital database in the US, with a secondary AF
diagnosis and matched controls that had neither a primary nor a
secondary AF diagnosis. We matched on patient age, discharge
date, facility type and primary diagnosis category. We used
regression models to estimate the incremental inpatient costs and
LOS due to secondary AF. We adjusted for comorbidities, demo-
graphic and hospital-speciﬁc factors. We repeated this analysis
for patients without cardiac predisposing factors (i.e. mitral valve
disease, heart failure, non-AF cardiac operation, chest pain and
congestive artery disease). RESULTS: The estimated 5.4 million
secondary AF discharges in the US during 2004 and 2005 had an
adjusted average inpatient cost of $12,292. This cost was $3532
more than the adjusted average inpatient cost for controls
without AF (P < 0.0001). Patients with secondary AF had an
adjusted average LOS of 7.8 days or 1.9 additional days com-
pared to controls without AF (P < 0.0001). The estimated 1.4
million secondary AF discharges without cardiac predisposing
factors had an adjusted average inpatient cost of $8956, an
increase of $1908 compared to controls without AF or cardiac
predisposing factors (P < 0.0001). Secondary AF patients
without cardiac predisposing factors had an adjusted average
LOS of 6.2 days or one additional day compared to controls
(P < 0.0001). CONCLUSIONS: Inpatient costs and LOS were
signiﬁcantly higher for patients with a secondary AF discharge
diagnosis when compared to controls that did not have an AF
diagnosis. These differences, although still signiﬁcant, were less
pronounced among patients without cardiac predisposing
factors. Further research is warranted to investigate how second-
ary AF is most cost-effectively treated.
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OBJECTIVES: Atherothrombosis is the leading cause of death
worldwide with huge economic burden. Peripheral arterial
disease (PAD), a marker of disseminated vascular disease, puts
patients at a high risk of atherothrombotic events. The REACH
Registry is an international prospective registry of 67,888
patients from 44 countries at risk of atherothrombosis due to
coronary artery disease (CAD), cerebrovascular disease (CVD)
and/or PAD, or the presence of3 atherothrombotic risk factors.
PAD at enrollment was identiﬁed on the basis of current inter-
mittent claudication with either ankle brachial index (ABI) < 0.9,
or history of lower limb revascularization (angioplasty/stenting,
peripheral bypass graft) or amputation. METHODS: We
examined 2-year rates of vascular-related hospitalizations and
associated costs in 1303 REACH patients from Germany with
established PAD at baseline. Poisson regression was used to
identify independent predictors of vascular hospitalizations. The
costs per DRG for vascular hospitalizations were derived from
the German 2004 Case Fees Catalogue. RESULTS: At baseline,
mean age was 68 years, 29% female, 46% diabetes, 76% had
ABI < 0.9, 56% had prior lower limb revascularization, 13%
prior amputation, 63% had other involved vascular territories
(479 CAD + PAD; 136 CVD + PAD; 205 CAD + CVD + PAD).
There were 360 (28%) patients who had 1 vascular hospital-
izations at 2 years. Signiﬁcant (p < 0.05) independent baseline
predictors of an increased hospitalization rate included diabetes,
female, ABI < 0.9, prior peripheral revascularization, prior
amputation, CAD, hypertension, decreasing age and prior
smoking. Mean vascular hospitalization costs per patient were:
€2595 overall; €3052 female/€2423 male; €3351/€1973 with/
without diabetes; €2773/€2394 with/without prior lower limb
revascularization; €2787/€2578 with/without prior amputation.
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